CRPOF - Ceapro Inc. Reports 2020 Second Quarter and Six-Month Financial Results and Operational Highlights

August, 20 2020 09:05 AM Ceapro Inc

– Record second quarter sales of $4,666,000 compared to $3,054,000 for second quarter 2019, representing a 53% increase and highest quarterly sales in Company’s history –

– R&D activities focused on the development of innovative delivery systems –

– Net profit of $1,077,000 for Q2 2020 vs. net loss of $559,000 for Q2 2019 –

– Cash generated from operations of $2,727,000 in 2020 vs $853,000 in 2019 –

– Maintained production operations during COVID-19 pandemic, providing our customers with essential products while ensuring the health and safety of our employees –

EDMONTON, Alberta, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the second quarter and the first six months ended June 30, 2020.

“We are extremely proud of our employees who worked tirelessly since the beginning of the year to deliver these excellent results despite the COVID-19 pandemic. Progress was made on all fronts from production operations with the largest volumes produced in Ceapro’s history to Research Engineering where the PGX group has successfully developed and optimized new products like yeast beta glucan as a potential inhalable therapeutic for COVID-19. As we continue to move forward and navigate operations during these unprecedented times, our focus remains on the health and safety of our associates, followed by business continuity,” stated Gilles Gagnon, M.Sc., MBA, President and CEO.

Corporate and Operational Highlights

Pipeline Development:

Announced expansion of collaborative research program with McMaster University to develop inhalable therapeutic for COVID-19;
Announced publication of positive results for a PGX-processed drug delivery system for accelerated burn wound healing;
Pursued the development of new PGX-dried chemical complexes for potential applications under various forms like pills, capsules, fast dissolving strips and face masks; and
Continued the monitoring of stability studies for liquid beta glucan and avenanthramides produced at the new manufacturing site as well as for the pharmaceutical grade dry powder formulation of avenanthramides.

Technology:

Made significant technical upgrades of PGX demo plant;
Completed technical assessment of available pieces of equipment world-wide for final decision on the type and location of future commercial scale PGX unit; and
Executed on research collaboration projects with University of Alberta and McMaster University for the impregnation of various bio actives using PGX-processed dry beta glucan and alginate as potential delivery systems for multiple applications in healthcare.

Production Operations:

Delivered the largest quantity of final product in Ceapro’s history; and
Initiated decommissioning of Leduc manufacturing site.

Corporate:

Advanced conversations with interested potential partners to utilize Ceapro’s innovative technologies; and
Pursued out-licensing discussions for PGX-processed new chemical complexes.

Subsequent to Quarter:

Announced publication of positive results from study evaluating avenanthramides in exercise-induced inflammation; and
Announced successful development of yeast beta glucan as a potential inhalable therapeutic for COVID-19 and other fibrotic end-point diseases of the lung.

Financial Highlights for the Second Quarter and the Six Month Period Ended June 30, 2020

Total sales of $4,666,000 for the second quarter of 2020 and $8,939,000 for the first six months of 2020 compared to $3,054,000 and $6,251,000 for the comparative periods in 2019. The 43% increase in sales for the first six months is mainly due to a significant increase in sales of avenanthramides as well as an increase in sales of beta glucan to China, compared to the same period in 2019.
Net profit of $1,077,000 for the second quarter of 2020 and $2,203,000 for the first six months of 2020 compared to a net loss of $559,000 and $1,195,000 for the comparative periods in 2019.
Excluding non-cash items, mainly amortization, adjusted net profit for the first six months in 2020 is $ 3,323,000 versus adjusted net loss of $24,600 for the first six months of 2019.
Cash flows generated from operations of $2,727,000 in 2020 vs $853,000 in 2019.
Positive working capital balance of $7,732,000 as of June 30, 2020.
Subsequent to quarter, made final payment clearing loan with Alberta Financial Service Corporation.

"Over the course of the second quarter, our operations executed and adapted well, delivering significantly improved results on both a sequential and year-over-year basis. This strong performance resulted in a record quarter for the Company, highlighting the resiliency of our business model focused on providing customers with essential, sustainable high-quality products. The ability of our business to successfully navigate through the challenging second quarter business environment is a testament to the commitment and hard work of our dedicated employees, and a measurable indication of the operational improvements and cost reduction initiatives being generated by our strategic investments of the past few years,” continued Mr. Gagnon.

“Looking ahead, while taking into account the ongoing potential economic impact related to COVID-19 and evolving consumption trends, we believe Ceapro is well-positioned to once again deliver a solid double-digit growth in sales over 2019. With a strong balance sheet, a group of dedicated people, and a solid base business coupled with the innovative technologies and products that we have developed to enable us to expand, Ceapro is poised to emerge as a successful Life Science company,” concluded Mr. Gagnon.




CEAPRO INC.


Consolidated Balance Sheets


Unaudited






June 30,
December 31,

2020
2019

$
$



ASSETS


Current Assets


Cash and cash equivalents
4,267,320
1,857,195
Trade receivables
3,058,551
3,659,541
Other receivables
90,411
46,812
Inventories (note 3)
1,261,494
669,005
Prepaid expenses and deposits
262,199
178,908




8,939,975
6,411,461
Non-Current Assets


Investment tax credits receivable
607,700
607,700
Deposits
85,755
85,755
Licences (note 4)
19,995
21,477
Property and equipment (note 5)
18,883,313
19,764,122
Deferred tax assets
378,643
378,643




19,975,406
20,857,697



TOTAL ASSETS
28,915,381
27,269,158



LIABILITIES AND EQUITY


Current Liabilities


Accounts payable and accrued liabilities
843,004
1,291,204
Current portion of long-term debt (note 6)
15,466
111,865
Current portion of lease liabilities (note 7)
272,145
265,123
Current portion of CAAP loan (note 9)
77,858
72,942




1,208,473
1,741,134
Non-Current Liabilities


Long-term lease liabilities (note 7)
2,637,776
2,775,627
CAAP loan (note 9)
67,074
61,580
Deferred tax liabilities
378,643
378,643




3,083,493
3,215,850



TOTAL LIABILITIES
4,291,966
4,956,984



Equity


Share capital (note 8 (b))
16,503,089
16,401,677
Contributed surplus (note 8 (e))
4,656,825
4,650,090
Retained earnings
3,463,501
1,260,407




24,623,415
22,312,174



TOTAL LIABILITIES AND EQUITY
28,915,381
27,269,158






CEAPRO INC.




Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)
Unaudited











Quarters Ended June 30,

Six Months Ended June 30,


2020

2019

2020
2019


$

$

$
$






Revenue (note 15)
4,665,971

3,053,727

8,939,345
6,250,657

Cost of goods sold
2,079,270

1,592,293

3,980,493
3,432,591






Gross margin
2,586,701

1,461,434

4,958,852
2,818,066






Research and product development
399,797

811,894

902,339
1,612,398

General and administration
838,263

878,620

1,703,297
1,611,639

Sales and marketing
29,207

95,102

77,435
202,780

Finance costs (note 12)
44,583

52,813

146,192
161,187






Income (loss) from operations
1,274,851

(376,995
)
2,129,589
(769,938
)





Other income (expenses) (note 11)
(197,812
)
(181,596
)
73,505
(425,281
)





Income (loss) before tax
1,077,039

(558,591
)
2,203,094
(1,195,219
)





Income taxes
-

-

-
-






Total comprehensive income (loss) for the period
1,077,039

(558,591
)
2,203,094
(1,195,219
)





Net income (loss) per common share (note 18):




Basic
0.01

(0.01
)
0.03
(0.02
)
Diluted
0.01

(0.01
)
0.03
(0.02
)





Weighted average number of common shares outstanding (note 18):




Basic
77,608,341

77,053,836

77,573,327
77,050,330

Diluted
77,980,876

77,053,836

77,930,529
77,050,330




CEAPRO INC.


Consolidated Statements of Cash Flows


Unaudited






2020

2019

Six Months Ended June 30,
$

$

OPERATING ACTIVITIES


Net income (loss) for the period
2,203,094

(1,195,219
)
Adjustments for items not involving cash


Finance costs
79,674

88,546

Transaction costs
1,108

3,080

Depreciation and amortization
920,521

912,751

Foreign exchange gain on long-term debt
-

(307
)
Accretion
10,410

14,561

Share-based payments
108,147

152,017

Net income (loss) for the period adjusted for non-cash items
3,322,954

(24,571
)
CHANGES IN NON-CASH WORKING CAPITAL ITEMS


Trade receivables
600,990

795,136

Other receivables
(43,599
)
24,248

Inventories
(592,489
)
(192,553
)
Prepaid expenses and deposits
(33,088
)
219,940

Accounts payable and accrued liabilities relating to operating activities
(448,200
)
119,050

Total changes in non-cash working capital items
(516,386
)
965,821

Net income (loss) for the period adjusted for non-cash and working capital items
2,806,568

941,250

Interest paid
(79,674
)
(88,546
)
CASH GENERATED FROM OPERATIONS
2,726,894

852,704

INVESTING ACTIVITIES


Purchase of property and equipment
(38,230
)
(27,611
)
Deposits relating to investment in equipment
(50,203
)
(53,239
)
Accounts payable and accrued liabilities relating to investing activities
-

(1,458
)
CASH USED IN INVESTING ACTIVITIES
(88,433
)
(82,308
)
FINANCING ACTIVITIES


Stock options exercised
-

13,783

Repayment of long-term debt
(97,507
)
(241,044
)
Repayment of lease liabilities
(130,829
)
(138,541
)
CASH USED IN FINANCING ACTIVITIES
(228,336
)
(365,802
)
Increase in cash and cash equivalents
2,410,125

404,594




Cash and cash equivalents at beginning of the period
1,857,195

1,844,134




Cash and cash equivalents at end of the period
4,267,320

2,248,728

The complete financial statements are available for review on SEDAR at https://www.sedar.com/DisplayProfile.do?lang=EN&issuerType=03&issuerNo=00010110 and on the Company’s website at www.ceapro.com.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Company Name:	Ceapro Inc
Stock Symbol:	CRPOF
Market:	OTC
Website:	ceapro.com

Twitter